News Sentiment

ENGN sentiment intelligence

enGene Holdings Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 45 Balanced news tone 70 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.90 Week of 10 Jul 2026
Weighted tone 45/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

74/100 classification confidence.

Company focus 62

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+6.7% over one week, +17.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

enGene appoints Michael Heffernan as board chairman By Investing.com

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 74/100 classification
One-week reaction 6.7% Price confirming higher
Trend fit Trend inactive 17.3% over four weeks
Fair value -74.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 43
Negative 17

Relevance

Why the article matched

Direct first
Direct company coverage 62
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 7
TradingKey 7
Investing.com 3
simplywall.st 3
Business Wire 2
The Business Journals 2
Investing.com South Africa 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 24
Analyst action 8
Regulatory and legal 3
Guidance 2
Deals and strategy 2
Capital return 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 70
Investing.com Australia Direct company coverage

enGene appoints Michael Heffernan as board chairman By Investing.com

enGene Therapeutics Inc. has appointed Michael Heffernan as its new Chairman of the Board, replacing Dr. Richard Glickman. This leadership change occurs as the company prepares for a pre-BLA meeting with the FDA and plans to submit its BLA for detalimogene voraplasmid in the seco

Tone
Negative 31/100
Event
Market update
Published
16 Jul 2026 17:40
Source
Investing.com Australia
TradingKey Direct company coverage

enGene Holdings Inc (ENGNW) Earnings Forecast: Future EPS & Revenue Growth Estimates

The TradingKey article provides an earnings forecast for enGene Holdings Inc (ENGNW), highlighting that relevant financial forecasting data for EPS, Revenue, and Net Profit has not yet been disclosed by the company. It notes the current stock price and market cap information but

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 22:10
Source
TradingKey
TradingKey Direct company coverage

enGene Holdings Inc (ENGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of enGene Holdings Inc (ENGN), including its current stock price, market cap, and a summary of various technical indicators and moving averages. The analysis highlights that based on moving averages and other technical indicators, the cu

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 10:10
Source
TradingKey
The Business Journals Direct company coverage

enGene Therapeutics

Ron Cooper has been appointed as the new CEO of enGene Holdings Inc. This news was featured in the Boston Business Journal, which regularly reports on local business developments. The article highlights this key leadership change within enGene Therapeutics.

Tone
Neutral 50/100
Event
Market update
Published
20 Jun 2026 19:39
Source
The Business Journals
Investing.com Direct company coverage

Morgan Stanley cuts Engene stock rating on reduced sales outlook

Morgan Stanley downgraded Engene Holdings Inc. to Underweight from Equalweight, reducing its sales estimates for the company's detalimogene treatment due to reduced confidence in its commercial prospects. The firm noted that physicians lack confidence in the LEGEND study supporti

Tone
Negative 9/100
Event
Guidance
Published
18 Jun 2026 08:40
Source
Investing.com
TradingKey Direct company coverage

enGene Holdings Inc (ENGNW) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of enGene Holdings Inc (ENGNW) focusing on its dividend and stock split history. It indicates that no dividends have been distributed over the past five years and no stock split data is available. The company's stock is currently trading at $0.28

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 06:40
Source
TradingKey
TradingKey Direct company coverage

enGene Holdings Inc (ENGNW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for enGene Holdings Inc (ENGNW) by business segments and regions. However, it explicitly states that the relevant data has not yet been disclosed by the company, rendering the report unable to provide the reques

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 06:40
Source
TradingKey
TradingKey Direct company coverage

enGene Holdings Inc (ENGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown overview for enGene Holdings Inc (ENGN). It states that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. The page also includes current stock p

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 19:40
Source
TradingKey
TradingKey Direct company coverage

enGene Holdings Inc (ENGNW) Institutional Confidence

This article provides details on the institutional confidence score for enGene Holdings Inc (ENGNW), noting a previous score of 0.00 with no change. It lists several institutional shareholders, including Forbion Capital Partners and BVF Partners L.P., along with their shareholdin

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 18:40
Source
TradingKey
TradingKey Direct company coverage

enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for enGene Holdings Inc (ENGN), indicating a "Buy" rating based on 13 analysts. It details expected EPS for the previous and next quarters, along with a target price suggesting a significant upside. The report also includes a peer compari

Tone
Positive 71/100
Event
Earnings
Published
17 Jun 2026 17:40
Source
TradingKey
Investing.com South Africa Direct company coverage

H.C. Wainwright cuts Engene stock price target on clinical setbacks By Investing.com

H.C. Wainwright has reduced its price target for Engene Holdings Inc. (NASDAQ:ENGN) to $4.00 from $6.00, while maintaining a Buy rating, following disappointing clinical updates and a significant decline in its stock price. Several other analyst firms, including Citizens, Raymond

Tone
Negative 18/100
Event
Analyst action
Published
17 Jun 2026 05:40
Source
Investing.com South Africa
The Business Journals Direct company coverage

EnGene slashes staff by 50% to preserve cash ahead of regulatory push

EnGene Holdings Inc., a genetic medicines company, has reduced its workforce by 50% to conserve cash. This restructuring comes as the company awaits critical data for its bladder-cancer gene therapy drug. The move aims to preserve financial resources during this pivotal period.

Tone
Negative 19/100
Event
Regulatory and legal
Published
16 Jun 2026 21:10
Source
The Business Journals
grafa.com Direct company coverage

enGene Therapeutics reports Q2 2026 financial results

enGene Therapeutics reported Q2 2026 financial results, including $285.2 million in cash, cash equivalents, and marketable securities, and a net loss of $30.2 million. The company plans to submit a Biologics License Application (BLA) with the FDA in the second half of 2026, drive

Tone
Negative 38/100
Event
Earnings
Published
15 Jun 2026 14:39
Source
grafa.com
Finviz Direct company coverage

ENGN - enGene Therapeutics Inc Stock Price and Quote

This article provides a detailed stock price quote and financial data for enGene Therapeutics Inc. (ENGN), a clinical-stage biotechnology company. It includes key financial metrics, insider and institutional ownership, performance indicators, and a comprehensive list of analyst r

Tone
Negative 29/100
Event
Analyst action
Published
05 Jun 2026 00:40
Source
Finviz